Melissa Kapulu

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu MC, Muthumbi E, Otieno E, Rossi O, Ferruzzi P, Necchi F, Acquaviva A, Martin LB, Orindi B, Mwai K, Kibet H, Mwanzu A, Bigogo GM, Verani JR, Mbae C, Nyundo C, Agoti CN, Nakakana UN, Conti V, Bejon P, Kariuki S, Scott JAG, Micoli F, Podda A
Front Immunol, (2024). 15:1340425

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu M, Manda-Taylor L, Balasingam S, Means G, Ayiro Malungu M, Bejon P, Chi PC, Chiu C, Church EC, Correa-Oliveira R, Day N, Durbin A, Egesa M, Emerson C, Jambo K, Mathur R, Metzger W, Mumba N, Nazziwa W, Olotu A, Rodgers J, Sinyiza F, Talaat K, Kamerling I, Weller C, Baay M, Neels P
Biologicals, (2024). :101747

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Cavaleri M, Kaslow D, Boateng E, Chen WH, Chiu C, Choy RKM, Correa-Oliveira R, Durbin A, Egesa M, Gibani M, Kapulu M, Katindi M, Olotu A, Pongsuwan P, Simuyandi M, Speder B, Talaat KR, Weller C, Wills B, Baay M, Balasingam S, Olesen OF, Neels P
Biologicals, (2024). :101745

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs LO, Campbell C, Abouyannis M, Otiende M, Kapulu M, Obiero CW, Hamaluba M, Ngetsa C, Andersson MI, Githinji G, Warimwe G, Baisley K, Scott JAG, Matthews PC, Etyang A
J Virus Erad, (2023). 9:100355

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria.Richie TL, Church LWP, Murshedkar T, Billingsley PF, James ER, Chen MC, Abebe Y, Natasha Kc Chakravarty S, Dolberg D, Healy SA, Diawara H, Sissoko MS, Sagara I, Cook DM, Epstein JE, Mordm�ller B, Kapulu M, Kreidenweiss A, Franke-Fayard B, Agnandji ST, L�pez Mikue MA, McCall MBB, Steinhardt L, Oneko M, Olotu A, Vaughan AM, Kublin JG, Murphy SC, Jongo S, Tanner M, Sirima SB, Laurens MB, Daubenberger C, Silva JC, Lyke KE, Janse CJ, Roestenberg M, Sauerwein RW, Abdulla S, Dicko A, Kappe SHI, Sim BKL, Duffy PE, Kremsner PG, Hoffman SL
Expert Rev Vaccines, (2023). 22:964-1007

The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study.Kariuki SN, Macharia AW, Makale J, Nyamu W, Hoffman SL, Kapulu MC, Bejon P, Rayner JC, Williams TN
Elife, (2023). 12:e83874

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.Odera DO, Tuju J, Mwai K, Nkumama IN, Fürle K, Chege T, Kimathi R, Diehl S, Musasia FK, Rosenkranz M, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA, Abdi AI, Chi PC, de Laurent Z, Jao I, Kamuya D, Kamuyu G, Makale J, Murungi L, Musyoki J, Muthui M, Mwacharo J, Kariuki S, Mwanga D, Mwongeli J, Ndungu F, Njue M, Nyangweso G, Kimani D, Ngoi JM, Musembi J, Ngoto O, Otieno E, Ooko M, Shangala J, Wambua J, Mohammed KS, Omuoyo D, Mosobo M, Kibinge N, Kinyanjui S, Bejon P, Lowe B, Marsh K, Marsh V, Abebe Y, Billingsley PF, Sim BKL, Hoffman SL, James ER, Richie TL, Audi A, Olewe F, Oloo J, Ongecha J, Ongas MO, Koskei N, Bull PC, Hodgson SH, Kivisi C, Imwong M, Murphy SC, Ogutu B, Tarning J, Winterberg M, Williams TN
Sci Transl Med, (2023). 15:eabn5993

Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study.Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, Acquaviva A, Necchi F, Obiero CW, Martin LB, Bejon P, Njuguna P, Micoli F, Podda A
Front Immunol, (2022). 13:971866

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.Musasia FK, Nkumama IN, Frank R, Kipkemboi V, Schneider M, Mwai K, Odera DO, Rosenkranz M, Furle K, Kimani D, Tuju J, Njuguna P, Hamaluba M, Kapulu MC, Wardemann H, CHMI-SIKA Study Team, Osier FHA
Nat Commun, (2022). 13:4098

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.Kimingi HW, Kinyua AW, Achieng NA, Wambui KM, Mwangi S, Nguti R, Kivisi CA, Jensen ATR, Bejon P, Kapulu MC, Abdi AI, Kinyanjui SM, CHMI-SIKA Study Team
Front Immunol, (2022). 13:894770

Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.Kibwana E, Kapulu M, Bejon P
Curr Top Microbiol Immunol, (2022). :

Shigella-Controlled Human Infection Models: Current and Future Perspectives.Clarkson KA, Porter CK, Talaat KR, Kapulu MC, Chen WH, Frenck RWJr, Bourgeois AL, Kaminski RW, Martin LB
Curr Top Microbiol Immunol, (2022). :

Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt.Mumba N, Njuguna P, Chi P, Marsh V, Awuor E, Hamaluba M, Mauncho C, Mwalukore S, Masha J, Mwangoma M, Kalama B, Alphan H, Wambua J, Bejon P, Kamuya D, Kapulu MC
Front Public Health, (2022). 10:793913

Ethical considerations around volunteer payments in a malaria human infection study in Kenya: an embedded empirical ethics study.Chi PC, Owino EA, Jao I, Bejon P, Kapulu M, Marsh V, Kamuya D
BMC Med Ethics, (2022). 23:46

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.Williams E, Craig K, Chiu C, Davies H, Ellis S, Emerson C, Jamrozik E, Jefford M, Kang G, Kapulu M, Kolstoe SE, Littler K, Lockett A, Elena Rey Messer J, McShane H, Saenz C, Selgelid MJ, Shah S, Smith PG, Yamazaki N
Vaccine, (2022). 40:3484-3489

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.Kapulu MC, Kimani D, Njuguna P, Hamaluba M, Otieno E, Kimathi R, Tuju J, Sim BKL, CHMI-SIKA Study Team
BMC Infect Dis, (2022). 22:86

Equity for excellence in academic institutions: a manifesto for change.Wedekind L, Noe A, Mokaya J, Tamandjou C, Kapulu M, Ruecker A, Kestelyn E, Zimba M, Khatamzas E, Eziefula AC, Mackintosh CL, Nascimento R, Ariana P, Best D, Gibbs E, Dunachie S, Hadley G, Ravenswood H, Young B, Kamau C, Marsh K, McShane H, Hale R, McPhilbin E, Ovseiko PV, Oxford Equity in Academia consortium, Surender R, Worland C, White LJ, Matthews PC
Wellcome Open Res, (2021). 6:142

Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders.Chi PC, Owino EA, Jao I, Olewe F, Ogutu B, Bejon P, Kapulu M, Kamuya D, Marsh V, CHMI-SIKA Study Team
Trials, (2021). 22:494

Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia.Kunda-Ng'andu EM, Simuyandi M, Kapulu M, Chirwa-Chobe M, Mwanyungwi-Chinganya H, Mwale S, Chilengi R, Sharma A
Wellcome Open Res, (2021). 6:31

Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.Jamrozik E, Littler K, Bull S, Emerson C, Kang G, Kapulu M, Rey E, Saenz C, Shah S, Smith PG, Upshur R, Weijer C, Selgelid MJ, WHO Working Group for Guidance on Human Challenge Studies in COVID
Vaccine, (2021). 39:633-640